Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study
暂无分享，去创建一个
K. Savage | M. Shipp | A. Ligon | A. Santoro | S. Ansell | P. Zinzani | S. Rodig | P. Armand | A. Younes | J. Kuruvilla | J. Timmerman | M. Trněný | S. Parker | A. Engert | M. Roemer | M. Fanale | V. Ratanatharathorn | G. Collins | Jonathon B. Cohen | Kazunobu Kato | B. Farsaci | J. Cohen